Description
This EASL Studio episode explores how alcohol worsens liver disease in patients with cardiometabolic risks, the stigma affecting diagnosis and care, and the latest therapeutic advances.
Key topics of discussion include:
- Interaction between alcohol and cardiometabolic risks
- Stigma and its impact on patient care
- Identifying at-risk patients with clinical markers
- Emerging therapies and research opportunities
Faculty
- Aleksander Krag (Moderator)
- Fredrik Åberg (Faculty)
- Maru Rinella (Faculty)
- Maja Thiele (Faculty)
This EASL Studio is supported by Boehringer Ingelheim. EASL has received no input from Boehringer Ingelheim with regards to the content of this programme.
Related episodes
- EASL Studio S5E9: Alcohol and the new nomenclature – A game-changer?
- EASL Studio S4E8: The central role of alcohol and food policies on liver health
- EASL Studio S4E3: A 360 approach to beat alcohol-related liver disease
- EASL Studio S3E5: JHEP Live: Stigma and alcohol
 |
If you are interested in steatotic liver disease, the next EASL SLD Summit 2025, 23-25 January in Estoril, Portugal, is made for you! Don't miss it and register now. |
ℹ️ Please click here to access the podcast version of this EASL Studio episode.